Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of mocertatug rezetecan in advanced solid tumors
2024-513860-25-00Phase 2Authorised
- Sponsor
- GSK
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of mocertatug rezetecan in Nonhematologic neoplasms and Oophoroma, sponsored by GSK. Primary endpoints: Safety and tolerability of mocertatug rezetecan and Pharmacokinetics of mocertatug rezetecan. Planned start Dec 2024; status: authorised.
02
Drugs
mocertatug rezetecan
03
Conditions
Nonhematologic neoplasmsOophoroma
Beyond the preview
Go deeper on 2024-513860-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513860-25-00.